SKYX Platforms notes Nasdaq board and audit committee non-compliance after director's death
SKYX Platforms said independent director Efrat L. Greenstein Brayer died on September 26, 2026, leaving the company out of compliance with Nasdaq rules requiring a majority-independent board and an audit committee of at least three members. Nasdaq sent a cure-period letter on September 30, 2026, and the filing says there is no immediate effect on the listing, but the company cannot assure it will regain compliance in time.
Key points
- Director Efrat L. Greenstein Brayer died on September 26, 2026; she sat on the audit, compensation and nominating committees.
- Company notified Nasdaq on September 28, 2026 of non-compliance with Listing Rules 5605(b)(1) and 5605(c)(2)(A).
- Nasdaq cure period ends at the earlier of the next annual meeting or September 26, 2027; if that meeting is before March 25, 2027, compliance is due by March 25, 2027.
- The filing states there is no immediate effect on the Nasdaq listing, but no assurance was given that compliance will be regained within the cure period.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.